Literature DB >> 28550199

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.

Michael Schmueck-Henneresse1,2,3,4, Bilal Omer4,5,6,7, Thomas Shum4,5,6,8, Haruko Tashiro4,5,6, Maksim Mamonkin4,5,6, Natalia Lapteva4,5,6, Sandhya Sharma4,5,6,8, Lisa Rollins4,5,6, Gianpietro Dotti4,5,6, Petra Reinke2,3, Hans-Dieter Volk9,3, Cliona M Rooney4,5,6,10,11.   

Abstract

The outcome of therapy with chimeric Ag receptor (CAR)-modified T cells is strongly influenced by the subset origin of the infused T cells. However, because polyclonally activated T cells acquire a largely CD45RO+CCR7- effector memory phenotype after expansion, regardless of subset origin, it is impossible to know which subsets contribute to the final T cell product. To determine the contribution of naive T cell, memory stem T cell, central memory T cell, effector memory T cell, and terminally differentiated effector T cell populations to the CD3 and CD28-activated CAR-modified T cells that we use for therapy, we followed the fate and function of individually sorted CAR-modified T cell subsets after activation with CD3 and CD28 Abs (CD3/28), transduction and culture alone, or after reconstitution into the relevant subset-depleted population. We show that all subsets are sensitive to CAR transduction, and each developed a distinct T cell functional profile during culture. Naive-derived T cells showed the greatest rate of proliferation but had more limited effector functions and reduced killing compared with memory-derived populations. When cultured in the presence of memory T cells, naive-derived T cells show increased differentiation, reduced effector cytokine production, and a reduced reproliferative response to CAR stimulation. CD3/28-activated T cells expanded in IL-7 and IL-15 produced greater expansion of memory stem T cells and central memory T cell-derived T cells compared with IL-2. Our strategy provides a powerful tool to elucidate the characteristics of CAR-modified T cells, regardless of the protocol used for expansion, reveals the functional properties of each expanded T cell subset, and paves the way for a more detailed evaluation of the effects of manufacturing changes on the subset contribution to in vitro-expanded T cells.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28550199      PMCID: PMC5536854          DOI: 10.4049/jimmunol.1601494

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases.

Authors:  Thorsten R Mempel; Sarah E Henrickson; Ulrich H Von Andrian
Journal:  Nature       Date:  2004-01-08       Impact factor: 49.962

2.  Optimization of a dendritic cell-based assay for the in vitro priming of naïve human CD4+ T cells.

Authors:  Janice M Moser; Emily R Sassano; Del C Leistritz; Jennifer M Eatrides; Sanjay Phogat; Wayne Koff; Donald R Drake
Journal:  J Immunol Methods       Date:  2009-11-17       Impact factor: 2.303

3.  Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency.

Authors:  Michael Schmueck-Henneresse; Radwa Sharaf; Katrin Vogt; Benjamin J D Weist; Sybille Landwehr-Kenzel; Henrike Fuehrer; Anke Jurisch; Nina Babel; Cliona M Rooney; Petra Reinke; Hans-Dieter Volk
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

4.  Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Christopher D Scott; Anthony J Leonardi; Tori N Yamamoto; Anthony C Cruz; Claudia Ouyang; Madhu Ramaswamy; Rahul Roychoudhuri; Yun Ji; Robert L Eil; Madhusudhanan Sukumar; Joseph G Crompton; Douglas C Palmer; Zachary A Borman; David Clever; Stacy K Thomas; Shashankkumar Patel; Zhiya Yu; Pawel Muranski; Hui Liu; Ena Wang; Francesco M Marincola; Alena Gros; Luca Gattinoni; Steven A Rosenberg; Richard M Siegel; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2015-12-14       Impact factor: 14.808

5.  Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.

Authors:  Matthias Wölfl; Philip D Greenberg
Journal:  Nat Protoc       Date:  2014-03-27       Impact factor: 13.491

6.  Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells.

Authors:  K Schlienger; N Craighead; K P Lee; B L Levine; C H June
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

7.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo.

Authors:  Ian F Hermans; Jonathan D Silk; Jianping Yang; Michael J Palmowski; Uzi Gileadi; Corinna McCarthy; Mariolina Salio; Franca Ronchese; Vincenzo Cerundolo
Journal:  J Immunol Methods       Date:  2004-02-01       Impact factor: 2.303

9.  In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.

Authors:  William Y Ho; Hieu N Nguyen; Matthias Wolfl; Juergen Kuball; Philip D Greenberg
Journal:  J Immunol Methods       Date:  2006-01-26       Impact factor: 2.303

10.  Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

Authors:  F Berard; P Blanco; J Davoust; E M Neidhart-Berard; M Nouri-Shirazi; N Taquet; D Rimoldi; J C Cerottini; J Banchereau; A K Palucka
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

View more
  19 in total

1.  CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.

Authors:  Isabelle Magalhaes; Ingrid Kalland; James N Kochenderfer; Anders Österborg; Michael Uhlin; Jonas Mattsson
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

Review 2.  Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy.

Authors:  Fei Yi; Nicholas Frazzette; Anthony C Cruz; Christopher A Klebanoff; Richard M Siegel
Journal:  Trends Mol Med       Date:  2018-06-04       Impact factor: 11.951

3.  CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Authors:  Hong Qin; Zhenyuan Dong; Xiuli Wang; Wesley A Cheng; Feng Wen; Weili Xue; Han Sun; Miriam Walter; Guowei Wei; D Lynne Smith; Xiuhua Sun; Fan Fei; Jianming Xie; Theano I Panagopoulou; Chun-Wei Chen; Joo Y Song; Ibrahim Aldoss; Clarisse Kayembe; Luisa Sarno; Markus Müschen; Giorgio G Inghirami; Stephen J Forman; Larry W Kwak
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

4.  Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Authors:  J Joseph Melenhorst; Michael C Milone; Saba Ghassemi; Selene Nunez-Cruz; Roddy S O'Connor; Joseph A Fraietta; Prachi R Patel; John Scholler; David M Barrett; Stefan M Lundh; Megan M Davis; Felipe Bedoya; Changfeng Zhang; John Leferovich; Simon F Lacey; Bruce L Levine; Stephan A Grupp; Carl H June
Journal:  Cancer Immunol Res       Date:  2018-07-20       Impact factor: 11.151

5.  Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.

Authors:  Christopher T Petersen; Mojibade Hassan; Anna B Morris; Jasmin Jeffery; Kunhee Lee; Neera Jagirdar; Ashley D Staton; Sunil S Raikar; Harold T Spencer; Todd Sulchek; Christopher R Flowers; Edmund K Waller
Journal:  Blood Adv       Date:  2018-02-13

6.  Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris.

Authors:  Jinmin Lee; Daniel K Lundgren; Xuming Mao; Silvio Manfredo-Vieira; Selene Nunez-Cruz; Erik F Williams; Charles-Antoine Assenmacher; Enrico Radaelli; Sangwook Oh; Baomei Wang; Christoph T Ellebrecht; Joseph A Fraietta; Michael C Milone; Aimee S Payne
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 7.  Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.

Authors:  Leidy D Caraballo Galva; Lun Cai; Yanxia Shao; Yukai He
Journal:  J Genet Genomics       Date:  2020-01-28       Impact factor: 4.275

8.  Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells.

Authors:  Bilal Omer; Paul A Castillo; Haruko Tashiro; Thomas Shum; Mai T A Huynh; Mara Cardenas; Miyuki Tanaka; Andrew Lewis; Tim Sauer; Robin Parihar; Natalia Lapteva; Michael Schmueck-Henneresse; Malini Mukherjee; Stephen Gottschalk; Cliona M Rooney
Journal:  Front Med (Lausanne)       Date:  2018-12-11

9.  Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation.

Authors:  Iva Xhangolli; Burak Dura; GeeHee Lee; Dongjoo Kim; Yang Xiao; Rong Fan
Journal:  Genomics Proteomics Bioinformatics       Date:  2019-06-20       Impact factor: 7.691

Review 10.  The role of small molecules in cell and gene therapy.

Authors:  Lewis L Brayshaw; Carlos Martinez-Fleites; Takis Athanasopoulos; Thomas Southgate; Laurent Jespers; Christopher Herring
Journal:  RSC Med Chem       Date:  2020-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.